These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 27918429)

  • 1. Correction: Budiarto, Bugi Ratno and Desriani. Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study. Sci. Pharm. 2016, 84, 103-111.
    Budiarto BR; Desriani
    Sci Pharm; 2016 Dec; 84(4):753. PubMed ID: 27918429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dataset reporting detection of breast cancer-related
    Budiarto BR; Desriani
    Data Brief; 2016 Dec; 9():689-695. PubMed ID: 27790634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study.
    Budiarto BR; Desriani
    Sci Pharm; 2016; 84(1):103-11. PubMed ID: 27110502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Brázda, V. and Coufal, J
    Brázda V; Coufal J
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30216985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: wai, m.g.C., et Al. A review of pinealectomy-induced melatonin-deficient animal models for the study of etiopathogenesis of adolescent idiopathic scoliosis. Int. J. Mol. Sci. 2014, 15, 16484-16499.
    Man GC; Wang WW; Yim AP; Wong JH; Ng TB; Lam TP; Lee SK; Ng BK; Wang CC; Qiu Y; Cheng JC
    Int J Mol Sci; 2015 Jan; 16(2):3017-8. PubMed ID: 25642756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Shakil, H.; Saleem, S. Genetic Deletion of Prostacyclin IP Receptor Exacerbates Transient Global Cerebral Ischemia in Aging Mice.
    Shakil H; Saleem S
    Brain Sci; 2021 May; 11(5):. PubMed ID: 34068448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.
    Nelson SE; Gould MN; Hampton JM; Trentham-Dietz A
    Breast Cancer Res; 2005; 7(3):R357-64. PubMed ID: 15987431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: Screening and Biosensor-Based Approaches for Lung Cancer Detection.
    Wang L
    Sensors (Basel); 2019 Oct; 19(20):. PubMed ID: 31614471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.
    Furrer D; Lemieux J; Côté MA; Provencher L; Laflamme C; Barabé F; Jacob S; Michaud A; Diorio C
    Breast; 2016 Dec; 30():191-196. PubMed ID: 27788409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
    Ignatiadis M; Kallergi G; Ntoulia M; Perraki M; Apostolaki S; Kafousi M; Chlouverakis G; Stathopoulos E; Lianidou E; Georgoulias V; Mavroudis D
    Clin Cancer Res; 2008 May; 14(9):2593-600. PubMed ID: 18451221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HER2 CD4
    De La Cruz LM; McDonald ES; Mick R; Datta J; Nocera NF; Xu S; Fisher CS; Czerniecki BJ
    Ann Surg Oncol; 2017 Apr; 24(4):1057-1063. PubMed ID: 27826664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her2 genotype and breast cancer progression in Korean women.
    An HJ; Kim NK; Oh D; Kim SH; Park MJ; Jung MY; Kang H; Kim SG; Lee KP; Lee KS
    Pathol Int; 2005 Feb; 55(2):48-52. PubMed ID: 15693849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
    Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
    Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility.
    Johnson KC
    J Pharm Sci; 2012 Feb; 101(2):681-9. PubMed ID: 21989679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim.
    Rutter JL; Chatterjee N; Wacholder S; Struewing J
    Epidemiology; 2003 Nov; 14(6):694-700. PubMed ID: 14569185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
    Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
    Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
    Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
    J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M
    Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.